Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...

Relative Risk

Relative Risk

Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Leukemia·2017

Same author

Latin America: the next region for haematopoietic transplant progress.

Bone marrow transplantation·2017

Same author

Alloreactivity: the Janus-face of hematopoietic stem cell transplantation.

Leukemia·2017

Same author

Latin America: the next region for haematopoietic transplant progress.

Bone marrow transplantation·2017

Same author

The EBMT-ELN working group recommendations on the prophylaxis and treatment of GvHD: a change-control analysis.

Bone marrow transplantation·2016

Same author

Allogeneic Bone Marrow Transplantation in Chronic Lymphocytic Leukemia: 17 Cases. Report of the EBMT.

Leukemia & lymphoma·2016

Same journal

Transplant outcomes for patients with severe acquired aplastic anemia over the age of 40 using busulfan, fludarabine, reduced-dose cyclophosphamide, and anti-thymocyte globulin conditioning regimen.

Bone marrow transplantation·2026

Same journal

A holistic prognostic model for leukemia-free survival after allogeneic transplantation in acute leukemia.

Bone marrow transplantation·2026

Same journal

Early software-assisted response predicts survival in a prospective cohort of 258 newly diagnosed cGvHD patients.

Bone marrow transplantation·2026

Same journal

Evaluation of a novel eHealth-facilitated, post HCT-integrated care model on implementation and rehospitalization: results from the Swiss SMILe hybrid-RCT.

Bone marrow transplantation·2026

Same journal

Impact of doublet post-transplant maintenance on outcomes in multiple myeloma: A propensity score matching analysis.

Bone marrow transplantation·2026

Same journal

A multimodal sexual health intervention among hematopoietic stem cell transplant recipients: mediating effects on quality of life and mood.

Bone marrow transplantation·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 1, 2026

Systematic Endobronchial Ultrasound - The Six Landmarks Approach

Systematic Endobronchial Ultrasound - The Six Landmarks Approach

Published on: August 11, 2023

The EBMT risk score.

¹Hematology, University Hospital, Basel, Switzerland. alois.gratwohl@unibas.ch

Bone Marrow Transplantation

|June 7, 2011

Summary

This summary is machine-generated.

The European Group for Blood and Marrow Transplantation (EBMT) risk score helps predict hematopoietic stem cell transplant (HSCT) outcomes. This score, based on five factors, guides personalized treatment decisions for patients with hematological disorders.

More Related Videos

Substernal Thyroid Biopsy Using Endobronchial Ultrasound-guided Transbronchial Needle Aspiration

Substernal Thyroid Biopsy Using Endobronchial Ultrasound-guided Transbronchial Needle Aspiration

Published on: November 10, 2014

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

Related Experiment Videos

Last Updated: Jun 1, 2026

Systematic Endobronchial Ultrasound - The Six Landmarks Approach

Systematic Endobronchial Ultrasound - The Six Landmarks Approach

Published on: August 11, 2023

Substernal Thyroid Biopsy Using Endobronchial Ultrasound-guided Transbronchial Needle Aspiration

Substernal Thyroid Biopsy Using Endobronchial Ultrasound-guided Transbronchial Needle Aspiration

Published on: November 10, 2014

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

Area of Science:

Hematology
Transplant Immunology
Oncology

Background:

Hematopoietic stem cell transplantation (HSCT) is a critical treatment for hematological disorders.
Accurate pre-transplant risk assessment is essential for optimizing patient outcomes.
Existing methods may not fully capture the complexity of individual patient risks.

Purpose of the Study:

To introduce and validate the European Group for Blood and Marrow Transplantation (EBMT) risk score.
To assess the score's utility in predicting outcomes for HSCT recipients.
To promote a risk-adapted, individualized strategy for HSCT decision-making.

Main Methods:

Development of the EBMT risk score incorporating five key factors: patient age, disease stage, time from diagnosis, donor type, and donor-recipient gender combination.
Additive scoring system ranging from 0 (best) to 7 (worst).
Validation across various acquired hematological disorders, allogeneic and autologous HSCT, and different conditioning intensities.

Main Results:

The EBMT risk score effectively stratifies patients based on predicted survival.
Survival is consistently worse for patients with higher scores (older age, advanced disease, longer diagnosis time, mismatched donor).
The score is applicable to diverse HSCT scenarios, including standard and reduced-intensity conditioning.

Conclusions:

The EBMT risk score is a simple, instant tool for pre-transplant risk assessment in HSCT.
It facilitates a shift from a 'donor vs. no donor' approach to a risk-adapted, individualized strategy.
Integration of the EBMT score with other risk factors can further refine prediction and guide clinical decisions.